Comments
Zydus Cadila has received final approval from the US health regulator to market Nifedipine extended-release tablets and Cholestyramine for oral suspension in the American market.
According to a BSE filing, the company will market Nifedipine extended-release tablets in the strengths of 30 mg, 60 mg, and 90 mg. The product will be manufactured at the group’s manufacturing facility at Moraiya, Ahmedabad. The tablets are used to treat high blood pressure and angina, Zydus Cadila said.
The company will also market Cholestyramine for oral suspension 4 g resin per pouch or scoopful, which is used along with a proper diet to lower cholesterol. The product will be manufactured at the group’s formulations manufacturing facility at Baddi in Himachal Pradesh.
Shares of Cadila Healthcare, the listed entity of the group, were trading up by 0.56 per cent at Rs 387.70 on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.